Appeal No. 2001-1290 Page 3
Application No. 08/950,032
combination with the female hormone estrogen or synthetic estrogen analogues,
as effective modulators of both PR and ER. On the other hand, antagonists to
PR are potentially useful in treating chronic disorders, such as certain hormone
dependent cancers of the breast, ovaries, and uterus, and in treating non-
malignant conditions such as uterine fibroids and endometriosis, a leading cause
of infertility in women. Similarly, AR antagonists, such as cyproterone acetate
and flutamide have proved useful in the treatment of hyperplasia an dancer of the
prostate.” Specification, pages 1-2.
The specification discloses that a number of quinoline derivatives are
agonists and/or antagonists for one or more of the PR, AR, ER, GR, and MR
steroid receptors. See pages 35 to 249 (disclosing synthesis of exemplary
compounds), pages 23 to 33 (listing representative compounds that are agonists
or antagonists for various receptors), and pages 255 to 262 (showing results of in
vitro and in vivo assays to determine agonistic and antagonistic activity with
respect to various receptors). The specification also discloses various conditions
or disorders that would be amenable to treatment with the disclosed compounds,
depending on their agonistic or antagonistic activity with respect to different
receptors. See pages 22-23.
Discussion
The claims are directed to therapeutic methods comprising administering
a quinoline derivative corresponding to one of three chemical formulae. See
claim 16. The examiner rejected the claims as nonenabled, based on a review of
the factors set out in In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007